Amgen (NASDAQ:AMGN) Sets New 52-Week High Following Dividend Announcement

Amgen Inc. (NASDAQ:AMGN) hit a new 52-week high during mid-day trading on Wednesday after the company announced a dividend. The company traded as high as $454.66 and last traded at $449.6390, with a volume of 1,283,695 shares trading hands. The stock had previously closed at $447.95.

The newly announced dividend which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s payout ratio is currently 62.65%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Argus increased their target price on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Barclays upped their target price on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, October 21st. Canaccord Genuity Group raised their price target on shares of Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Guggenheim lowered their price objective on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 13th. Finally, Mizuho upped their price objective on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $389.71.

Amgen Stock Performance

The stock has a market cap of $243.09 billion, a P/E ratio of 27.94, a price-to-earnings-growth ratio of 3.21 and a beta of 0.41. The firm’s 50-day moving average is $418.42 and its two-hundred day moving average is $372.80. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen Inc. will post 22.96 EPS for the current year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease, showing statistically significant and clinically meaningful improvements in systemic disease activity and patient-reported dryness. The data strengthen the company’s autoimmune-disease pipeline and could support future commercial opportunities. Amgen autoimmune disease data
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, payable December 11 to shareholders of record November 20. The announcement supports the stock’s income appeal and signals continued confidence in cash generation. Amgen fourth-quarter dividend
• Positive Sentiment: Goldman Sachs maintained a Buy rating, while TD Cowen also rated Amgen Buy. The supportive analyst views add to positive sentiment around the company’s pipeline and earnings prospects. Goldman Sachs Amgen rating
• Positive Sentiment: Jefferies raised its price target to $428 from $410, and Barclays increased its target to $400 from $380, reflecting improved expectations despite both targets remaining below the recent share price. Jefferies Amgen price target
• Neutral Sentiment: Amgen plans to present additional data on autoimmune and rare diseases at the American College of Rheumatology meeting, creating potential near-term catalysts but also leaving investors focused on the quality and commercial implications of the disclosures. Amgen ACR data presentation
• Negative Sentiment: The FDA issued a warning letter over promotional material for Amgen’s Vectibix cancer drug. Although the immediate financial impact is unclear, regulatory criticism creates compliance and reputational risks. FDA warning regarding Vectibix promotion

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last ninety days. Insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in Amgen by 6.1% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 85,905 shares of the medical research company’s stock worth $36,210,000 after buying an additional 4,920 shares in the last quarter. Partners Wealth Management LLC bought a new position in Amgen during the third quarter valued at approximately $328,000. Soltis Investment Advisors LLC raised its stake in shares of Amgen by 8.8% during the third quarter. Soltis Investment Advisors LLC now owns 31,750 shares of the medical research company’s stock worth $13,383,000 after acquiring an additional 2,578 shares in the last quarter. Choreo LLC boosted its stake in shares of Amgen by 1.5% in the 3rd quarter. Choreo LLC now owns 18,598 shares of the medical research company’s stock valued at $7,839,000 after purchasing an additional 278 shares in the last quarter. Finally, Interchange Capital Partners LLC boosted its stake in shares of Amgen by 1.3% in the 3rd quarter. Interchange Capital Partners LLC now owns 2,139 shares of the medical research company’s stock valued at $902,000 after purchasing an additional 28 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.